Phase 2 N=11 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Melanoma · Meningioma · Breast Cancer
Primary: Percentage of Participants With a Response — 10; 50 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Muscle Property, Alignment and Joint Loading in People With Knee Osteoarthritis
Osteoarthritis, Knee
Primary: Change of External Knee Adduction Moment as Assessed by Visual Motion Analysis System — 0.50 Nm/kg
N/A N=51 EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
Nausea
Primary: Time to Nausea Reduction by 50% by Visual Analog Scale. — 4.3; 3.5 Minutes
N/A N=20 Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline
Phase 1 N=27 Experimental Human Infection With Neisseria Gonorrhoeae
Gonococcal Infection
Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…
Phase 3 N=74 Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
Influenza
Primary: Safety and Tolerability, as Measured by the Number of Adverse Events. — 17; 9; 1; 5 Participants
N/A N=44 Seizure Detection Using SEDline During Therapeutic Hypothermia in Cardiac Arrest Victims
Cardiac Arrest
Primary: Percentage of Seizure-positive and Seizure-negative That Were Correctly Classified by the SEDline in All Evaluated Cases — 100 percentage of seizures
N/A N=59 Mnemonic Strategy Versus Spaced Retrieval Training in Those With Mild Cognitive Impairment
Mild Cognitive Impairment
Primary: Percent of Correct Object Location Associations Assessed up to 1 Month Post-treatment — 80.0; 62.45 percent correct — p=<.001
Phase 3 N=141 Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
Chronic Hepatitis C
Primary: Proportion of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 136 Participants
Phase 2 N=2 Verapamil as Therapy for Children and Young Adults With Dravet Syndrome
Dravet Syndrome
Primary: Change in Number of General Tonic-clonic Seizures From Week 8 (Baseline) Visit to Week 12 Visit — 39; 14 General tonic-clonic seizures
N/A N=43 Neural Changes Associated With a Mindfulness-based Intervention for Young Adults With Childhood Maltreatment
Depression · Anxiety · PTSD
Primary: Changes in Subjects' Perceived Stress Level — -5.526; 1.000 score on a scale
N/A N=740 Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy in Reducing Insomnia in Cancer Survivors
Cancer Survivor · Insomnia · Malignant Neoplasm
Primary: Mean Change in the ISI Comparing YOCAS vs. CBT-I — -3.61; -7.22; -2.19 units on a scale — p=<.0001
Phase 2 N=597 Blue Sky Study: Impact of Milk and Vitamin D for Child Growth and Health
Vitamin d Deficiency
Primary: Serum 25-hydroxyvitamin D Concentrations in Schoolchildren — 8; 8; 10; 7 ng/ml
Phase 2 N=44 Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
Alzheimer's Disease
Primary: Adverse Events (AEs) by Body System — 5; 2; 6; 5 Adverse Events
Phase 4 N=17 Xyrem and Brain Dopamine in Narcolepsy
Narcolepsy With Cataplexy · Healthy Controls
Primary: [C-11]Raclopride BPND at 1 Hour Post Xyrem — 2.94; 3.01; 3.80; 3.70 BPND (Binding Potential) — p=0.31